Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPB-101 Ethno-bridging Study in Healthy Adults
NCT05653479Phase 1Completed
- Sponsor
- Upstream Bio
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vereckitug in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) (4 arms), sponsored by Upstream Bio. Primary endpoints: Maximum Observed Concentration at Day 85, Time to Maximum Observed Concentration at Day 85 and 1 more. Started Dec 2022; status: completed.
02
Drugs
vereckitug
03
Conditions
asthmachronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05653479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653479.